Cathie Wood, of ARK Genomic Revolution ETF(NYSE: ARKG) explains the multi-trillion dollar opportunity in the Genomics Revolution: CAR-T, CRISPR, and DNA Sequencing
Related Articles
Zylo and Hoth Therapeutics (NASDAQ: HOTH) Forge Partnership to Develop Endocannabinoid-Based Drug to Treat Lupus
August 29, 2019
admin
Healthcare, Newsmakers
Comments Off on Zylo and Hoth Therapeutics (NASDAQ: HOTH) Forge Partnership to Develop Endocannabinoid-Based Drug to Treat Lupus
Greenville, SC, Aug. 22, 2019 — Zylo Therapeutics, dedicated to bringing innovative topical technologies to multiple facets of medicine, has entered into a definitive partnership agreement with Hoth Therapeutics (NASDAQ: HOTH) to develop a new treatment for […]
U.S. Food and Drug Administration (FDA) Grants Emergency IND for Two Coronavirus Patients Treated in New York with CytoDyn’s (OTC: CYDY) Leronlimab
March 19, 2020
admin
Healthcare, Newsmakers
Comments Off on U.S. Food and Drug Administration (FDA) Grants Emergency IND for Two Coronavirus Patients Treated in New York with CytoDyn’s (OTC: CYDY) Leronlimab
A leading academic medical center has administered the test medication, leronlimab, in two of their sickest COVID-19 patients. Neither patient has had any serious adverse reactions to leronlimab since it was administered. We are hopeful […]
CytoDyn (OTC: CYDY) and Samsung BioLogics Formalize Manufacturing Partnership
May 30, 2019
admin
Healthcare, Newsmakers
Comments Off on CytoDyn (OTC: CYDY) and Samsung BioLogics Formalize Manufacturing Partnership
INCHEON, South Korea, May 30, 2019 – CytoDyn Inc., (OTC: CYDY) a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications and Samsung BioLogics met at […]